<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39381118</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2233-7385</ISSN><JournalIssue CitedMedium="Print"><Volume>60</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Chonnam medical journal</Title><ISOAbbreviation>Chonnam Med J</ISOAbbreviation></Journal><ArticleTitle>Corticosteroid Therapy Duration and Dosage According to the Timing of Treatment Initiation for Post-COVID-19 Organizing Pneumonia.</ArticleTitle><Pagination><StartPage>166</StartPage><EndPage>173</EndPage><MedlinePgn>166-173</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4068/cmj.2024.60.3.166</ELocationID><Abstract><AbstractText>COVID-19 can lead to pulmonary complications, including organizing pneumonia. Steroids are essential in treating post-COVID-19 organizing pneumonia. However, research on the clinical benefits of initiating steroid treatment early for this condition is limited. To investigate the steroid initiation time in its association with treatment duration and corticosteroid dose for treating post-COVID-19 organizing pneumonia, we analyzed the data of 91 patients with post-COVID-19 organizing pneumonia at Chonnam National University Hospital between October 2020 and December 2022. Patients were categorized into early and late groups based on time from COVID-19 diagnosis to steroid initiation time for organizing pneumonia. The mean time interval between COVID-19 infection and steroid initiation time for treating organizing pneumonia, was 18.4±8.6 days. Within the early treatment group (treatment initiated &lt;18.4 days after COVID-19), which included 55 patients, the mean duration of steroid treatment was 43.1±18.3days. In contrast, the late treatment group (initiated ≥18.4 days after COVID-19), which consisted of 36 patients, had a longer mean duration of steroid treatment 59.1±22.6 days) (p&lt;0.01). Regarding corticosteroid dosing, the early treatment group had an average dosage of 0.5±0.3 mg/kg/day, in contrast to the late group, which averaged 0.8±0.3 mg/kg/day (p&lt;0.01). Regression analysis showed steroid initiation time significantly influenced treatment duration (β=0.80 , p&lt;0.01) and dosage (β=0.03, p&lt;0.01). The clinical benefits of early steroid treatment for post-COVID-19 organizing pneumonia may lie in its association with reduced steroid treatment duration and dosage.</AbstractText><CopyrightInformation>© Chonnam Medical Journal, 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Chang-Seok</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Division of Pulmonology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Hwa-Kyung</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Division of Pulmonology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jae-Kyeong</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Division of Pulmonology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kho</LastName><ForeName>Bo-Gun</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>Division of Pulmonology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Tae-Ok</ForeName><Initials>TO</Initials><AffiliationInfo><Affiliation>Division of Pulmonology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Hong-Joon</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Division of Pulmonology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Yong-Soo</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Division of Pulmonology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Sung-Chul</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Division of Pulmonology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yu-Il</ForeName><Initials>YI</Initials><AffiliationInfo><Affiliation>Division of Pulmonology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Chonnam Med J</MedlineTA><NlmUniqueID>101564659</NlmUniqueID><ISSNLinking>2233-7393</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Corticosteroid Therapy</Keyword><Keyword MajorTopicYN="N">Early Therapeutic Initiation</Keyword><Keyword MajorTopicYN="N">Post-COVID-19 Organizing Pneumonia</Keyword></KeywordList><CoiStatement>CONFLICT OF INTEREST STATEMENT: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>4</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39381118</ArticleId><ArticleId IdType="pmc">PMC11458313</ArticleId><ArticleId IdType="doi">10.4068/cmj.2024.60.3.166</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020;8:807–815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228727</ArticleId><ArticleId IdType="pubmed">32422178</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronson KI, Podolanczuk AJ. Lungs after COVID-19: evolving knowledge of post-COVID-19 interstitial lung disease. Ann Am Thorac Soc. 2021;18:773–774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8086543</ArticleId><ArticleId IdType="pubmed">33929309</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka KE, Perry W, Huang T, Farver CF, Myers JL. Usual interstitial pneumonia is the most common finding in surgical lung biopsies from patients with persistent interstitial lung disease following infection with SARS-CoV-2. EClinicalMedicine. 2021;42:101209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8609167</ArticleId><ArticleId IdType="pubmed">34841234</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiralongo F, Palermo M, Distefano G, Vancheri A, Sambataro G, Torrisi SE, et al. Cryptogenic organizing pneumonia: evolution of morphological patterns assessed by HRCT. Diagnostics (Basel) 2022;10:262</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7277545</ArticleId><ArticleId IdType="pubmed">32365469</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazdyrev E, Panova M, Zherebtsova V, Burdenkova A, Grishagin I, Novikov F, et al. The hidden pandemic of COVID-19-induced organizing pneumonia. Pharmaceuticals (Basel) 2022;15:1574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9780828</ArticleId><ArticleId IdType="pubmed">36559025</ArticleId></ArticleIdList></Reference><Reference><Citation>Achkar M, Jamal O, Chaaban T. Post-COVID lung disease(s) Ann Thorac Med. 2022;17:137–144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9374125</ArticleId><ArticleId IdType="pubmed">35968401</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordier JF. Organising pneumonia. Thorax. 2000;55:318–328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1745738</ArticleId><ArticleId IdType="pubmed">10722773</ArticleId></ArticleIdList></Reference><Reference><Citation>Siafarikas C, Stafylidis C, Tentolouris A, Samara S, Eliadi I, Makrodimitri S, et al. Radiologically suspected COVID-19-associated organizing pneumonia responding well to corticosteroids: a report of two cases and a review of the literature. Exp Ther Med. 2022;24:453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9199065</ArticleId><ArticleId IdType="pubmed">35720626</ArticleId></ArticleIdList></Reference><Reference><Citation>Myall KJ, Mukherjee B, Castanheira AM, Lam JL, Benedetti G, Mak SM, et al. Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment. Ann Am Thorac Soc. 2021;18:799–806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8086530</ArticleId><ArticleId IdType="pubmed">33433263</ArticleId></ArticleIdList></Reference><Reference><Citation>Segala FV, Sgalla G, Salvati F, Berardini L, Negri M, Nardella E, et al. Adjunctive corticosteroid treatment for organizing pneumonia in COVID-19 patients with persistent respiratory failure. Respir Med. 2021;187:106571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352674</ArticleId><ArticleId IdType="pubmed">34388415</ArticleId></ArticleIdList></Reference><Reference><Citation>Khaw CR, Richardson C, Bhowmik A, Agbetile J, Rajakulasingam RK. Use of corticosteroid in persistent post-COVID-19 interstitial lung disease. Ann Am Thorac Soc. 2021;18:1599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8489875</ArticleId><ArticleId IdType="pubmed">34191693</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravaglia C, Doglioni C, Chilosi M, Piciucchi S, Dubini A, Rossi G, et al. Clinical, radiological and pathological findings in patients with persistent lung disease following SARS-CoV-2 infection. Eur Respir J. 2022;60:2102411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8932282</ArticleId><ArticleId IdType="pubmed">35301248</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues JP, Júnior R, Pinto M, Santos A, Gerardo R, Miguel A, et al. Organizing pneumonia due to COVID-19: the experience of one year in an intensive care unit. Eur Respir J. 2022;60(Suppl 66):3989</Citation></Reference><Reference><Citation>Pogatchnik BP, Swenson KE, Sharifi H, Bedi H, Berry GJ, Guo HH. Radiology-pathology correlation demonstrating organizing pneumonia in a patient who recovered from COVID-19. Am J Respir Crit Care Med. 2020;202:598–599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7427386</ArticleId><ArticleId IdType="pubmed">32609531</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieksiene K, Zaveckiene J, Malakauskas K, Vaguliene N, Zemaitis M, Miliauskas S. Post COVID-19 organizing pneumonia: the right time to interfere. Medicina (Kaunas) 2021;57:283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8003092</ArticleId><ArticleId IdType="pubmed">33803690</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Jin C, Wu CC, Zhao H, Liang T, Liu Z, et al. Organizing pneumonia of COVID-19: time-dependent evolution and outcome in CT findings. PLoS One. 2020;15:e0240347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7657520</ArticleId><ArticleId IdType="pubmed">33175876</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito A, Ishida T, Tachibana H, Arita M, Yamazaki A, Washio Y. Utility of procalcitonin for differentiating cryptogenic organising pneumonia from community-acquired pneumonia. Clin Chem Lab Med. 2019;57:1632–1637.</Citation><ArticleIdList><ArticleId IdType="pubmed">31120857</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghu G, Meyer KC. Cryptogenic organising pneumonia: current understanding of an enigmatic lung disease. Eur Respir Rev. 2021;30:210094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9488952</ArticleId><ArticleId IdType="pubmed">34407978</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA, Ware LB National Institutes of Health, National Heart, Lung, and Blood Institute ARDS Network. Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS. Chest. 2007;132:410–417.</Citation><ArticleIdList><ArticleId IdType="pubmed">17573487</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasir M, Goyal A, Sonthalia S. Corticosteroid adverse effects. Treasure Island: StatPearls Publishing; 2024.</Citation><ArticleIdList><ArticleId IdType="pubmed">30285357</ArticleId></ArticleIdList></Reference><Reference><Citation>Bill PM, Castellví I, Martínez-Martínez L, Aparicio F, Franquet T, Vidal OS, et al. Diagnostic value of serum KL-6 in interstitial lung disease: preliminary results from an European cohort. Eur Respir J. 2018;52(Suppl 62):PA2959</Citation></Reference><Reference><Citation>Ebihara S, Niu K, Ebihara T, Kuriyama S, Hozawa A, Ohmori-Matsuda K, et al. Impact of blunted perception of dyspnea on medical care use and expenditure, and mortality in elderly people. Front Physiol. 2012;3:238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3389490</ArticleId><ArticleId IdType="pubmed">22783203</ArticleId></ArticleIdList></Reference><Reference><Citation>Burdon JG, Pain MC, Rubinfeld AR, Nana A. Chronic lung diseases and the perception of breathlessness: a clinical perspective. Eur Respir J. 1994;7:1342–1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">7925915</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahmer T, Borzikowsky C, Lieb W, Horn A, Krist L, Fricke J, et al. NAPKON study group. Severity, predictors and clinical correlates of post-COVID syndrome (PCS) in Germany: a prospective, multi-centre, population-based cohort study. EClinicalMedicine. 2022;51:101549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9289961</ArticleId><ArticleId IdType="pubmed">35875815</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwee TC, Kwee RM. Chest CT in COVID-19: what the radiologist needs to know. Radiographics. 2020;40:1848–1865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7587296</ArticleId><ArticleId IdType="pubmed">33095680</ArticleId></ArticleIdList></Reference><Reference><Citation>Parotto M, Gyöngyösi M, Howe K, Myatra SN, Ranzani O, Shankar-Hari M, et al. Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations. Lancet Respir Med. 2023;11:739–754.</Citation><ArticleIdList><ArticleId IdType="pubmed">37475125</ArticleId></ArticleIdList></Reference><Reference><Citation>An TJ, Lee YJ, Park JE, Lee EG, Kim Y, Kang SY, et al. Benefits of early systemic corticosteroid in clinical deterioration of post-COVID-19 interstitial lung disease. Tuberc Respir Dis (Seoul) 2022;85:358–360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9537655</ArticleId><ArticleId IdType="pubmed">35950320</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazor R, Vandevenne A, Pelletier A, Leclerc P, Court-Fortune I, Cordier JF, et al. Cryptogenic organizing pneumonia. Characteristics of relapses in a series of 48 patients. Am J Respir Crit Care Med. 2000;162:571–577.</Citation><ArticleIdList><ArticleId IdType="pubmed">10934089</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>